Dysautonomia emerged as a frequent companion of chronic musculoskeletal pain
A cross-sectional study in chronic musculoskeletal pain found a striking burden of dysautonomia, with abnormal autonomic symptom scores present in nearly three-quarters of patients and only a small minority of healthy controls. The size of the gap is clinically hard to ignore: 74% versus 11%, with an adjusted relative risk of 7.4.
The finding matters because chronic pain rarely behaves as a purely local problem. Autonomic regulation sits upstream of vascular tone, heart rate variability, gastrointestinal function, sweating, and stress responses, all of which can become distorted when pain becomes persistent. In that setting, dysautonomia is not an incidental symptom cluster; it can shape how patients experience pain, fatigue, dizziness, and day-to-day function.
What the cohort showed across inflammatory and non-inflammatory disease
Investigators recruited patients with clinician-confirmed musculoskeletal conditions and pain lasting longer than 12 weeks, then compared them with healthy participants matched for age and sex distribution. Of 896 screened patients, 342 entered the study, alongside 57 controls. Participants completed the Composite Autonomic Symptom Score-31, the Brief Pain Inventory, and the Hospital Anxiety and Depression Scale.
A COMPASS-31 score of 17 or higher defined dysautonomia. By that threshold, prevalence was similarly elevated in both major clinical subgroups: 76% in inflammatory conditions and 72% in non-inflammatory conditions. The near-parallel rates argue against a narrow disease-specific explanation and point instead to a broader relationship between persistent musculoskeletal pain and autonomic dysregulation.
Pain clinic and rheumatology services often separate patients by diagnosis first and symptom burden second. This dataset suggests the autonomic phenotype may cut across those boundaries.
Pain intensity tracked with autonomic burden
Dysautonomia did not appear at random within the chronic pain population. Severity of pain rose with the likelihood of autonomic dysfunction, with risk increasing by 1.27 per point on the Brief Pain Inventory.
That pattern is biologically plausible. Ongoing nociceptive input can drive sympathetic activation, baroreflex disruption, and altered central pain processing. Over time, autonomic imbalance may no longer be just a response to pain; it may become part of the mechanism that helps maintain pain chronicity. In practical terms, patients with more severe pain may also be the ones most likely to report orthostatic symptoms, bowel disturbance, temperature intolerance, palpitations, or generalized autonomic complaints.
The study design does not prove directionality, and it cannot separate cause from consequence. Even so, the association between pain severity and dysautonomia provides a useful bedside signal: autonomic symptoms should not be dismissed as unrelated background noise in patients whose pain scores are climbing.
Why the autonomic nervous system belongs in chronic pain assessment
The autonomic nervous system is closely tied to pain modulation. Sympathetic output can amplify vigilance and bodily arousal, while parasympathetic withdrawal may blunt recovery and resilience. In persistent musculoskeletal disease, those shifts may intensify symptom reporting, worsen sleep, and complicate rehabilitation. For patients already burdened by inflammatory pain, systemic dysregulation may add another layer of disability even when structural damage alone does not explain the clinical picture.
A prevalence rate of 74% changes the framing. Dysautonomia is not a rare comorbidity appearing at the margins of chronic pain care; it is common enough to influence case assessment, symptom interpretation, and perhaps future treatment selection. A patient with refractory pain and prominent autonomic complaints may need a broader evaluation than analgesic escalation alone.
What the comparison group makes clear
Healthy controls showed dysautonomia in 11% of cases, a much lower rate than in the chronic pain cohort but not zero. That background prevalence matters because it reminds clinicians that autonomic symptom screening is not disease-specific and can identify issues in otherwise healthy individuals as well. The contrast, however, remains large enough to indicate a meaningful association with chronic musculoskeletal pain.
The study’s cross-sectional structure limits causal inference and leaves unanswered whether autonomic dysfunction precedes pain chronicity, develops alongside it, or reflects a shared underlying susceptibility. Psychological measures were included, signaling an interest in the interaction between autonomic symptoms, pain, anxiety, and depression, but the abstract does not provide the corresponding association data. Those missing details are important because anxiety and depression can both magnify symptom reporting and overlap with autonomic complaints.
Why the prevalence signal should alter clinical conversations
For rheumatologists, pain specialists, and rehabilitation clinicians, the practical message is straightforward: autonomic symptoms deserve routine attention in chronic musculoskeletal pain. Dizziness on standing, palpitations, sweating changes, gastrointestinal upset, and heat intolerance may carry more diagnostic weight when they occur in a patient with persistent pain and high Brief Pain Inventory scores. A COMPASS-31 threshold of 17 or higher offers one structured way to screen for that burden.
The study also broadens the conversation around inflammatory and non-inflammatory disease. Similar dysautonomia rates in both groups suggest the autonomic problem is not confined to autoimmune or inflammatory pathology. Chronic pain itself may be the common denominator, or at least one of several converging drivers.
Limits of the evidence and the next questions
Because this was a cross-sectional study, it cannot establish temporal sequence or treatment effect. It also comes from a screened cohort in which only 342 of 896 patients ultimately participated, so selection effects may have influenced the observed prevalence. Healthy controls were fewer in number than patients, and the abstract does not provide granular subgroup details beyond the broad inflammatory versus non-inflammatory split.
Still, the main signal is difficult to overlook. Dysautonomia was common, severe pain tracked with greater autonomic burden, and the association held across musculoskeletal disease categories. The next step is to determine whether autonomic screening identifies a clinically distinct subgroup that responds differently to pain management, rehabilitation, or autonomic-directed therapy.